Mohamed El-Shimy, Minister of the Public Enterprises Sector, stated that the ministry places the highest priority on supporting its affiliated pharmaceutical companies through comprehensive development and modernisation programmes. These efforts aim to upgrade production lines, enhance operational efficiency, and adopt the latest technological systems. The initiatives are designed to meet domestic demand and strengthen competitiveness in export markets.
During an extensive inspection tour of Cairo Pharmaceuticals and Chemical Industries at its Shubra facility, a subsidiary of the Holding Company for Pharmaceuticals, Chemicals and Medical Supplies, Minister El-Shimy praised the company's role as one of Egypt's most important national industrial entities. He described it as a leading model for a strong and advanced pharmaceutical industry capable of meeting local needs and supporting exports to regional and international markets, thereby enhancing the global standing of Egyptian medicines. He also commended the efforts and dedication of its workforce.
The tour focused on reviewing progress in operations and assessing production processes following a series of comprehensive upgrades aligned with the latest international quality standards. El-Shimy inspected the advanced production infrastructure, which includes 25 integrated production lines covering a wide range of pharmaceutical forms such as plain and coated tablets, hard and soft capsules, syrups and oral drops, ointments and suppositories, effervescent and regular granulated powders, ophthalmic preparations and ampoules. He also visited the upgraded quality control laboratories, scientific research and development units, quality assurance department, and technical development department, all operating in accordance with Good Manufacturing Practices.
El-Shimy stressed that keeping pace with global developments in the pharmaceutical industry is a central pillar of the ministry's strategy, emphasizing the importance of investing in scientific research, innovation, and continuous modernisation of production lines to ensure sustainable growth and competitive quality for Egyptian pharmaceutical products. He highlighted that providing high-quality medicines at affordable prices remains a core objective, as the development of affiliated companies contributes to strengthening drug security, meeting citizens' needs, and reinforcing confidence in domestically produced medicines.
Company officials outlined ongoing efforts to modernise production lines with the latest systems, expand into foreign markets through new partnerships, develop competitive pharmaceutical products, increase investment in research and innovation, and strengthen corporate social responsibility initiatives. El-Shimy reaffirmed the ministry's full support for export expansion plans and partnerships, noting their role in boosting exports of Egyptian medicines and creating new growth opportunities. He also emphasized the importance of continued on-site monitoring of all affiliated companies to ensure the highest standards of production efficiency and quality.
Founded in 1962, Cairo Pharmaceuticals has more than six decades of experience and is regarded as one of the pillars of the pharmaceutical industry in Egypt and the Middle East. The company's financial results for the first quarter of fiscal year 2025/2026 showed a 93.2% year-on-year increase in profits, with net profits reaching EGP 143.6m, while sales rose to approximately EGP 651.8m. It is a leading producer of several widely used medicines in the Egyptian market, including Brizolin, Spasmopyralgin, Triactin, Pyral, Novlo, Sedalin, Tussilar, Dexazone, Analerg, Dramamine, and Spicton, among other essential, safe, and effective pharmaceutical products serving local and regional markets.